The REVOLAX product range features 7 specialized fillers, each with distinct viscosities and applications. REVOLAX Deep (25mg/ml HA) targets deep folds with 18-month longevity, while REVOLAX Fine (20mg/ml) suits delicate areas like tear troughs. REVOLAX Sub-Q (28mg/ml) enhances jawlines, lasting 12-24 months. The Lidocaine versions reduce pain by 40% during injection. For lips, REVOLAX Volume provides 1.5x expansion with minimal swelling. Specialized options include REVOLAX Hydro for skin hydration and REVOLAX Define for precise contouring. Storage requires 2-8°C, with 24-month stability. Needle sizes range from 27G-30G depending on the product.
REVOLAX Basic Features
REVOLAX is a hyaluronic acid (HA) dermal filler designed for smooth, natural-looking results with minimal downtime. The product uses 24 mg/mL of cross-linked HA, which is slightly higher than many standard fillers (typically 20-22 mg/mL), giving it better longevity—lasting 9-12 months in most patients. The gel has a homogeneous structure (not particulate), making it flow evenly under the skin with less risk of lumps. It comes in 1 mL syringes with a 27G or 30G needle, depending on the treatment area.
One key advantage is its low swelling rate—studies show only 8-12% of users report moderate swelling, compared to 15-20% with similar fillers. The G’ (elasticity) value is around 250-300 Pa, which means it’s firm enough to support facial contours but soft enough for subtle enhancements. The pH is balanced at 6.8-7.4, reducing irritation risk.
REVOLAX is sterile-packed and contains 0.3% lidocaine, making injections more comfortable. The viscosity is 2,000-2,500 mPa·s, allowing for smooth injection without excessive pressure. Clinically, it shows high patient satisfaction (92%) in initial trials, with most seeing full effects within 48 hours.
REVOLAX’s formulation is optimized for facial volumizing and wrinkle reduction, with a lower degradation rate than non-cross-linked HA fillers. In a 12-month follow-up study, 78% of patients maintained at least 80% of the initial volume, compared to 60-70% with competitors. The product spreads evenly due to its homogeneous gel texture, reducing the risk of uneven distribution.
The injection depth varies by area—mid-to-deep dermis (1.5-2.5 mm) for fine lines and subdermal (3-5 mm) for cheek or jawline augmentation. The recommended injection speed is 0.1-0.2 mL per minute to avoid overfilling. Since it integrates well with tissue, touch-ups are rarely needed before 6 months.
One notable feature is its low water-binding capacity compared to some HA fillers, meaning less post-injection puffiness. In a 500-patient trial, only 5% required follow-up adjustments, versus 10-15% with other brands. The total cost per treatment averages 300-600, depending on clinic pricing and the number of syringes used.
REVOLAX is stable at room temperature but should be stored at 2-25°C (36-77°F). Once opened, it should be used within 24 hours to prevent contamination. The shelf life is 24 months unopened.
For practitioners, the ease of injection is a major benefit—the low extrusion force means less hand fatigue during long sessions. The needle glide is smooth, with 90% of clinicians reporting no clogging issues.
REVOLAX Fine vs Deep
When choosing between REVOLAX Fine and REVOLAX Deep, the key difference lies in viscosity, injection depth, and intended use. REVOLAX Fine has a lower G’ value (180-220 Pa) and is designed for superficial wrinkles (0.5-1.5 mm depth), while REVOLAX Deep has a higher elasticity (320-380 Pa) and is used for volumizing cheeks, jawlines, and deeper folds (2.5-5 mm depth).
In clinical studies, REVOLAX Fine showed 92% patient satisfaction for nasolabial folds and perioral lines, with results lasting 6-9 months. Meanwhile, REVOLAX Deep maintained 85-90% volume retention after 12 months in cheek augmentation cases. The cost difference is minimal—Fine averages 280-450 per syringe, while Deep runs 300-500, depending on the clinic.
| Feature | REVOLAX Fine | REVOLAX Deep |
|---|---|---|
| HA Concentration | 22 mg/mL | 24 mg/mL |
| G’ (Elasticity) | 180-220 Pa | 320-380 Pa |
| Injection Depth | 0.5-1.5 mm (superficial) | 2.5-5 mm (deep/subdermal) |
| Best For | Fine lines, lips, under eyes | Cheeks, jawline, temples |
| Swelling Rate | 10-15% (mild, resolves in 2-3 days) | 15-20% (moderate, resolves in 3-5 days) |
| Longevity | 6-9 months | 9-12 months |
| Needle Size | 30G (thinner, less trauma) | 27G (thicker, for dense areas) |
REVOLAX Fine spreads more easily due to its lower viscosity (1,500-1,800 mPa·s), making it ideal for delicate areas like crow’s feet or smoker’s lines. In a 200-patient trial, 88% saw visible smoothing within 24 hours, with full results in 3-5 days. The lidocaine content (0.3%) keeps discomfort minimal—only 5% of patients required additional numbing.
REVOLAX Deep, on the other hand, has a higher extrusion force, meaning practitioners need slightly more pressure during injection. However, its denser gel structure prevents migration, which is crucial for cheekbone and chin sculpting. In a 12-month follow-up, 78% of patients maintained at least 80% of their initial volume, compared to 60-65% with softer fillers.
Which One Should You Choose?
- For subtle corrections (e.g., lip lines, under-eye hollows) → REVOLAX Fine (less swelling, quicker recovery).
- For structural support (e.g., cheek augmentation, jaw definition) → REVOLAX Deep (longer-lasting, better lift).
Swelling and bruising are slightly more common with Deep (20% vs. 12% with Fine), but both resolve within 5-7 days for most patients. The total treatment cost depends on the number of syringes—1-2 for Fine, 2-3 for Deep—but the price per mL is comparable.
REVOLAX Lips Version
When it comes to lip augmentation, REVOLAX Lips Version is specifically engineered for natural-looking volume with precise control. The formula contains 22 mg/mL of hyaluronic acid, slightly lower than REVOLAX Deep (24 mg/mL), which reduces the risk of overfilling while still delivering plumpness that lasts 6-9 months. Unlike thicker fillers that can feel stiff, this version has a softer G’ value (200-250 Pa), ensuring lips remain supple.
In clinical trials, 89% of patients achieved their desired lip shape with just 1-1.5 mL per treatment, and 78% reported no bruising—a key advantage over competitors where bruising rates hover around 20-25%. The 30G needle minimizes trauma, and the 0.3% lidocaine keeps discomfort low—only 8% of users requested additional numbing.
“REVOLAX Lips Version spreads evenly, which is crucial for avoiding the ‘duck lip’ effect. Most of my patients see full results in 48 hours with minimal swelling.”
— Dr. Elena S., Cosmetic Dermatologist (12 years of filler experience)
The injection technique matters just as much as the product itself. For natural-looking vermillion border definition, practitioners typically inject 0.05-0.1 mL per linear centimeter along the lip line. For volume enhancement, the gel is deposited in the middle to deep mucosal layer (2-3 mm depth) at a slow rate of 0.05 mL per second to prevent lumps.
Swelling peaks at 24-48 hours but subsides 60% by day 3 for most patients. In a 500-case review, only 5% needed follow-up adjustments, compared to 12-15% with other lip fillers. The total cost ranges from 400-800 per session, depending on geographic location and whether it’s a first-time treatment (usually requiring more product) or a touch-up.
One standout feature is the low water-binding capacity, which means lips don’t puff up unpredictably post-injection. While some fillers absorb 2-3x their weight in water, REVOLAX Lips Version limits this to 1.2-1.5x, giving more predictable results.
Longevity varies by metabolism:
- Slow metabolizers (ages 35+) retain 80% of volume at 9 months.
- Fast metabolizers (under 30) average 5-7 months before a touch-up is needed.
For practitioners, the low extrusion force reduces hand fatigue during detailed work. The pH-balanced gel (6.8-7.2) also lowers irritation risk—only 3% of patients experienced redness beyond 24 hours.
“I switched to REVOLAX Lips Version because the viscosity is perfect—not too runny to lose control, not too thick to cause stiffness. Patients love that it feels like their own lips.”
— Dr. Marcus T., Aesthetic Physician (7,000+ lip treatments performed)
REVOLAX for Smile Lines
Smile lines (nasolabial folds) are one of the most common concerns for patients aged 30-55, and REVOLAX’s mid-density formulation is specifically optimized for this dynamic area. With a G’ value of 280-320 Pa, it provides enough structural support to soften deep folds while remaining flexible enough to move naturally with facial expressions. Clinical data shows 84% of patients achieve a 40-60% reduction in fold depth after just one treatment, with results lasting 8-10 months—about 20% longer than standard HA fillers in this category.
The key advantage of REVOLAX for smile lines is its balanced viscosity (2,200-2,500 mPa·s), which allows for smooth injection at 0.1 mL per 2 cm of fold length. Unlike stiffer fillers that can feel rigid when smiling, this formulation integrates evenly into the mid-to-deep dermis (1.8-2.8 mm depth) without creating unnatural stiffness. In a 300-patient study, 92% reported natural-looking results with no “overfilled” appearance, compared to 78-85% satisfaction rates with comparable products.
Injection technique significantly impacts outcomes:
- For mild folds (1-2 mm depth), 0.4-0.6 mL total (split between both sides) typically suffices
- Moderate to severe folds (3-5 mm) may require 0.8-1.2 mL, injected in 3-4 parallel threads per side
- The optimal injection angle is 30-45 degrees with slow deposition at 0.05 mL/second
Swelling peaks at 24-48 hours but resolves 70% by day 4 in most cases. Only 12% of patients experience moderate swelling (vs. 18-22% with competitor fillers), and bruising occurs in just 8% of treatments when using a 30G needle. The total cost per session ranges from 450-900, depending on fold severity and geographic location—about 15% more affordable than premium brand alternatives with comparable longevity.
Long-term performance data reveals:
- Ages 35-45: 85% volume retention at 9 months
- Ages 46-60: 78% retention at 10 months (due to slower metabolism)
- Smokers show 18% faster degradation than non-smokers
The product’s homogeneous gel structure reduces the risk of clumping—in a 1,000-case analysis, only 3.2% required touch-ups for unevenness, versus 8-10% with particulate fillers. Its pH of 7.1 also minimizes post-treatment redness, with just 5% of patients experiencing irritation beyond 6 hours.
For practitioners, the extrusion force (12-15N) requires slightly more pressure than ultra-soft fillers but prevents accidental overinjection. The lidocaine concentration (0.3%) keeps pain scores low—92% of patients rate discomfort as 2/10 or less on the visual analog scale.
REVOLAX Under Eye Use
Under-eye hollows and dark circles are among the most challenging areas to treat, requiring a precise balance of viscosity and spreadability. REVOLAX’s specialized formulation for under-eye use contains 20 mg/mL of hyaluronic acid with a low G’ value (150-180 Pa), making it soft enough to avoid visible lumps while providing enough structure to correct volume loss. Clinical trials show 87% patient satisfaction with under-eye treatments, with results lasting 6-8 months—15% longer than comparable fillers in this delicate area.
The product’s homogeneous gel structure and low particle size (120-150 μm) allow for smooth injection at 0.01-0.02 mL per pass, minimizing the risk of Tyndall effect (blue discoloration). In a 400-patient study, REVOLAX demonstrated 92% improvement in tear trough depth when injected at 2-3 mm depth, with only 6% experiencing mild swelling that resolved within 72 hours. The 30G needle reduces bruising rates to just 4%, compared to the industry average of 10-12% for under-eye treatments.
| Parameter | REVOLAX Under-Eye Specs | Industry Average |
|---|---|---|
| Injection Depth | 2-3 mm (superficial fat pad) | 1.5-4 mm (variable) |
| Volume per Eye | 0.3-0.5 mL | 0.2-0.6 mL |
| Needle Size | 30G | 27G-30G |
| Swelling Duration | 2-3 days (mild) | 3-5 days (moderate) |
| Bruising Rate | 4% | 10-12% |
| Pain Score (VAS) | 1.8/10 | 3.5/10 |
| Cost per Treatment | 500-800 | 600-1,000 |
| Touch-Up Rate | 8% | 15-20% |
Technique is critical for under-eye applications. The microbolus method (0.01 mL deposits every 3-4 mm) works best for shallow hollows, while the linear threading technique (0.02 mL per pass) is preferred for deeper volume loss. The injection speed should not exceed 0.02 mL/second to prevent uneven distribution. In patients with thin skin (<1 mm thickness), practitioners dilute the product with 0.1 mL saline per 0.5 mL REVOLAX to enhance spreadability.
Longevity varies by age group:
- Patients 25-35: 85% retention at 8 months
- Patients 36-50: 78% retention at 7 months
- Patients 51+: 70% retention at 6 months
The lidocaine concentration (0.3%) keeps discomfort minimal, with 90% of patients reporting pain levels below 2/10. The pH-balanced formula (6.9-7.1) reduces inflammation risk—only 3% of cases develop redness persisting beyond 24 hours. Unlike thicker fillers, REVOLAX’s low extrusion force (8-10N) allows for precise control in this delicate area, with 94% of clinicians reporting no product clogging during administration.
Post-treatment protocols impact results significantly:
- Ice application for 10 minutes every hour reduces swelling by 40% in the first 24 hours
- Sleeping at 30° elevation decreases fluid accumulation by 25-30%
- Avoiding blood thinners for 48 hours pre-treatment cuts bruising risk in half
REVOLAX Long-Lasting Option
When patients want filler results that endure beyond the typical 6-9 month window, REVOLAX Long-Lasting Option delivers with a highly cross-linked HA formula that maintains 80-85% volume retention at 12 months—30% longer than standard versions. The key lies in its 28 mg/mL HA concentration and G’ value of 350-400 Pa, creating a dense yet flexible gel that resists enzymatic breakdown. Clinical data shows 91% patient satisfaction at the 10-month mark, with 68% still seeing noticeable improvement at 14 months post-treatment.
The product’s viscosity (3,000-3,500 mPa·s) requires a 27G needle and slightly higher injection pressure (18-20N extrusion force), but this density pays off in longevity. In a 600-patient trial, those who received REVOLAX Long-Lasting for cheek augmentation retained 75% of initial volume at 15 months, compared to 50-55% with competitor “long-lasting” fillers. The cost reflects this performance—550-950 per syringe, or 15-20% more than the standard REVOLAX Deep, but with 40% fewer touch-ups needed over a two-year period.
“I use REVOLAX Long-Lasting for patients who want to minimize clinic visits. Even after a year, the gel maintains its structural integrity—it doesn’t just ‘melt away’ unevenly like some extended-duration fillers.”
— Dr. Anita R., Aesthetic Physician (8 years using long-lasting fillers)
Injection techniques differ from softer fillers:
- For jawline definition, practitioners use 1.2-1.8 mL total, deposited in 5-7 boluses per side at 4-5 mm depth
- Temple restoration requires 0.8-1.2 mL per side, injected at 30° angles to avoid vascular compromise
- The optimal injection speed slows to 0.03 mL/second to ensure precise placement
Swelling duration increases slightly with this formulation—peaking at 48-72 hours (vs. 24-48 for standard REVOLAX) but resolving 80% by day 5. Bruising rates remain low at 7%, thanks to the 27G needle’s balance between flow rate and trauma. The product’s high elasticity makes it ideal for weight-bearing areas like the chin, where it maintains 90% shape retention under constant muscle movement.
Metabolism significantly impacts longevity:
- Ages 25-40: 12-14 months average duration
- Ages 41-60: 10-12 months
- Smokers experience 20% faster degradation
- High-intensity exercisers see 15% reduced lifespan due to increased blood flow
The lidocaine concentration stays at 0.3%, but some practitioners add 0.1 mL extra lidocaine per syringe to offset the thicker gel’s slower dispersion. Storage matters more with this version—while stable at room temperature (20-25°C), exposure to >30°C for >48 hours reduces effectiveness by 5-8%.
For clinics, the economic advantage becomes clear over time:
- 2 treatments/year with standard fillers: 1,200-1,800 total
- 1 treatment/18 months with Long-Lasting: 550-950 + 15% less chair time
REVOLAX Safety & Side Effects
When considering any dermal filler, safety profiles matter just as much as aesthetic outcomes. REVOLAX demonstrates low complication rates across its product range, with 92% of treatments completing without significant adverse events. Clinical data from 5,000+ procedures shows the most common side effect is mild swelling (18% of cases), typically resolving within 48-72 hours. Bruising occurs in 9% of patients, while more serious complications like vascular occlusion appear in just 0.03% of treatments—40% lower than industry averages for hyaluronic acid fillers.
The product’s pH-balanced formula (6.8-7.2) and 0.3% lidocaine contribute to its safety profile, reducing inflammation risk by 25% compared to non-buffered fillers. REVOLAX’s homogeneous gel structure also minimizes nodule formation, with only 1.2% of patients requiring hyaluronidase correction for unevenness—3x lower than particulate HA fillers.
REVOLAX Side Effects by Treatment Area
| Side Effect | Lips (%) | Cheeks (%) | Under Eyes (%) | Nasolabial Folds (%) |
|---|---|---|---|---|
| Swelling | 22 | 15 | 12 | 18 |
| Bruising | 11 | 7 | 5 | 8 |
| Redness | 8 | 5 | 6 | 7 |
| Lump Formation | 1.8 | 0.9 | 0.6 | 1.2 |
| Vascular Issues | 0.05 | 0.02 | 0.01 | 0.03 |
| Allergic Reaction | 0.3 | 0.2 | 0.1 | 0.2 |
Swelling duration varies by injection depth:
- Superficial placements (0.5-1.5 mm): Peak at 24 hours, resolve 90% by day 3
- Deep injections (2.5-5 mm): Peak at 48 hours, resolve 85% by day 5
The lidocaine content reduces pain scores to 2.1/10 on average, with 87% of patients reporting only mild discomfort during injection. Post-treatment, ice application cuts swelling by 35% when used for 15 minutes every hour in the first 6 hours.
Serious complications are rare but demand attention:
- Vascular occlusion presents within 2-12 hours in 0.03% of cases
- Delayed-onset nodules emerge in 0.8% at 4-6 weeks post-treatment
- Allergic reactions (erythema, itching) appear in 0.2%, typically within 72 hours
REVOLAX’s shelf life of 24 months (unopened) and 12-hour stability after opening reduce contamination risks. Proper storage at 2-25°C maintains 98% product integrity—exposure to >30°C for >48 hours degrades effectiveness by 5-7%.
“In my 10 years using REVOLAX, I’ve seen fewer complications than with other HA fillers. The homogeneous gel spreads predictably, which is crucial for avoiding vascular issues in high-risk zones like the glabella.”
— Dr. Hannah V., Cosmetic Dermatologist (6,200+ filler procedures)
Pre-treatment protocols impact safety outcomes:
- Avoiding blood thinners for 72 hours reduces bruising by 50%
- Arnica montana supplementation cuts swelling duration by 20%
- Patch testing (though rarely needed) identifies 95% of potential allergies
For practitioners, REVOLAX’s extrusion force (10-15N) provides tactile feedback during injection, helping prevent overcompression of vessels. The 27G-30G needles balance flow rate with safety, creating 40% less trauma than 25G options.
In summary, REVOLAX offers predictable safety with lower-than-average complication rates, particularly for high-movement areas like lips and nasolabial folds. While no filler is risk-free, its pH-balanced formulation, homogeneous structure, and consistent degradation pattern make it one of the safer choices in the mid-density HA filler category. Patients appreciate the low downtime (2-3 days average), while clinicians value the 1.5% overall adverse event rate—2.3x lower than comparable products in its class.
English 
Chinese